Anders Martin-Löf
Direttore Finanziario/CFO presso BIOARCTIC AB
Patrimonio netto: 42 851 $ in data 30/06/2024
Profilo
Anders Martin-Löf is currently serving as an Independent Director at Cantargia AB, a Director at Oncopeptides Incentive AB, a Director at Lisa Martin-Löf Konsultbyrå AB, a Director at Affibody Medical AB, and the Chief Financial Officer & Secretary at BioArctic AB.
Previously, he held the position of Chief Financial Officer & Deputy CEO at Oncopeptides AB from 2018 to 2021.
He also worked as the Director of Investor Relations at Biovitrum AB, Director at Sciencecap Stockholm AB, CFO, Investor Relations & Press Contact at RaySearch Laboratories AB, CFO at Extenda AB, CFO at A3P Biomedical AB, Head of Investor Relations at Swedish Orphan Biovitrum AB, and Chief Financial Officer at Wilson Therapeutics AB.
Mr. Martin-Löf obtained his undergraduate degree from the University of Stockholm, his graduate degree from the Royal Institute of Technology, and another graduate degree from ENSIMAG.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
BIOARCTIC AB CLASS B
0.00% | 31/03/2024 | 1 000 ( 0.00% ) | 21 605 $ | 30/06/2024 |
CANTARGIA AB
0.03% | 31/12/2023 | 50 000 ( 0.03% ) | 21 246 $ | 30/06/2024 |
Posizioni attive di Anders Martin-Löf
| Società | Posizione | Inizio |
|---|---|---|
| CANTARGIA AB | Direttore/Membro del Consiglio | 01/01/2018 |
| BIOARCTIC AB | Direttore Finanziario/CFO | 01/06/2023 |
| Lisa Martin-Löf Konsultbyrå AB | Direttore/Membro del Consiglio | - |
| Oncopeptides Incentive AB | Direttore/Membro del Consiglio | - |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Direttore/Membro del Consiglio | 01/12/2021 |
Precedenti posizioni note di Anders Martin-Löf
| Società | Posizione | Fine |
|---|---|---|
| ONCOPEPTIDES AB | Direttore Finanziario/CFO | 08/11/2021 |
| WILSON THERAPEUTICS AB | Direttore Finanziario/CFO | 01/08/2018 |
| RAYSEARCH LABORATORIES AB | Direttore Finanziario/CFO | 02/07/2015 |
| SWEDISH ORPHAN BIOVITRUM AB | Contatto Relazioni con gli Investitori | 01/07/2007 |
| ░░░ ░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░ | - |
Formazione di Anders Martin-Löf
| Royal Institute of Technology | Graduate Degree |
| ENSIMAG | Graduate Degree |
| University of Stockholm | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| RAYSEARCH LABORATORIES AB | Technology Services |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| CANTARGIA AB | Health Technology |
| ONCOPEPTIDES AB | Health Technology |
| BIOARCTIC AB | Health Technology |
| Aziende private | 8 |
|---|---|
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Wilson Therapeutics AB
 Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden. | Health Technology |
| Sciencecap Stockholm AB | |
Extenda AB
 Extenda AB Information Technology ServicesTechnology Services Extenda AB develops point-of-sale technology (POS) solutions. Its product suite include transaction engine, selfscan, mobile POS, and self checkout. The firm also offers support, service and maintenance, and catalogue services. The company was founded by Peter Carlman in 1982 and is headquartered in Stockholm, Sweden. | Technology Services |
| Lisa Martin-Löf Konsultbyrå AB | |
| Oncopeptides Incentive AB | |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Health Technology |
A3P Biomedical AB
 A3P Biomedical AB Medical/Nursing ServicesHealth Services A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors. | Health Services |
- Borsa valori
- Insiders
- Anders Martin-Löf
